
Biotechnology · Nasdaq: VRTX
Vertex Pharmaceuticals earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 11 Feb 2027
Latest: Q3 2026
Vertex closed its Crinetics acquisition, adding rare endocrine as a fourth commercial pillar, and now awaits a November 30 FDA decision on povetacicept that could open a fifth in renal.
Vertex closed the Crinetics acquisition on September 1, adding PALSONIFY, a once-daily oral acromegaly drug that holds more than 40% of patients starting or switching therapy. ALYFTREK keeps taking patients from TRIKAFTA in cystic fibrosis. CASGEVY won FDA approval for children as young as 2. JOURNAVX became the most prescribed branded oral pain medicine in the U.S. as prescriptions kept climbing.
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $2.9B * |
| Q1 2025 | $2.8B |
| Q2 2025 | $3.0B |
| Q3 2025 | $3.1B |
| Q4 2025 | $3.2B * |
| Q1 2026 | $3.0B |
| Q2 2026 | $3.3B |
| Q3 2026 | $3.4B |
Data
| Q1 2025 | $2.49 |
| Q2 2025 | $3.99 |
| Q3 2025 | $4.20 |
| Q1 2026 | $4.02 |
| Q2 2026 | $4.31 |
| Q3 2026 | $2.56 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 35.2% |
| Q1 2025 | 22.7% |
| Q2 2025 | 38.8% |
| Q3 2025 | 38.6% |
| Q4 2025 | 37.8% |
| Q1 2026 | 38.1% |
| Q2 2026 | 37.4% |
| Q3 2026 | 20.7% |
Data
| Q4 2024 | $492.0M |
| Q1 2025 | $778.2M |
| Q2 2025 | $927.4M |
| Q3 2025 | $1.1B |
| Q4 2025 | $348.6M |
| Q1 2026 | $1.3B |
| Q2 2026 | $1.0B |
| Q3 2026 | $545.8M |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.9Bd | $2.8B | $3.0B | $3.1B | $3.2Bd | $3.0B | $3.3B | $3.4B |
| Operating income | $1.0Bd | $630.1M | $1.2B | $1.2B | $1.2Bd | $1.1B | $1.2B | $712.9M |
| Operating margin | 35.2% | 22.7% | 38.8% | 38.6% | 37.8% | 38.1% | 37.4% | 20.7% |
| Net income | $913.0Md | $646.3M | $1.0B | $1.1B | $1.2Bd | $1.0B | $1.1B | $653.6M |
| Diluted EPS | — | $2.49 | $3.99 | $4.20 | — | $4.02 | $4.31 | $2.56 |
| Operating cash flow | $584.6Md | $818.9M | $1.1Bd | $1.2Bd | $498.0Md | $1.4B | $1.1Bd | $643.1Md |
| Capital expenditure | $92.6Md | $40.7M | $145.7Md | $101.8Md | $149.4Md | $133.4M | $112.2Md | $97.3Md |
| Free cash flow | $492.0M | $778.2M | $927.4M | $1.1B | $348.6M | $1.3B | $1.0B | $545.8M |
| R&D expense | $998.7Md | $979.7M | $978.4M | $977.7M | $973.7Md | $961.6M | $993.8M | $1.3B |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 3 Nov 202610-Q for the period ended 30 Sep 2026SEC ↗
- 4 Aug 202610-Q for the period ended 30 Jun 2026SEC ↗
- 5 May 202610-Q for the period ended 31 Mar 2026SEC ↗
- 13 Feb 202610-K for the period ended 31 Dec 2025SEC ↗
- 4 Nov 202510-Q for the period ended 30 Sep 2025SEC ↗
- 5 Aug 202510-Q for the period ended 30 Jun 2025SEC ↗
- 6 May 202510-Q for the period ended 31 Mar 2025SEC ↗
- 13 Feb 202510-K for the period ended 31 Dec 2024SEC ↗